Scribe Therapeutics Inc. – Trademark Portfolio
Entity Type: 03
Scribe Therapeutics Inc. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 3 trademarks are registered and 3 are pending. Notable registered marks include SCRIBE, CRISPR BY DESIGN, and X SCRIBE THERAPEUTICS. The owner is based in Alameda, CA.
1150 Marina Village Parkway
Alameda, CA 94501
Showing of trademarks Trademarks
Trademark Classifications
Scribe Therapeutics Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Scribe Therapeutics Inc. have?
Scribe Therapeutics Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 pending, 4 abandoned.
What trademark classes does Scribe Therapeutics Inc. file in?
Scribe Therapeutics Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Scribe Therapeutics Inc.'s most well-known trademarks?
Scribe Therapeutics Inc.'s registered trademark portfolio includes well-known marks such as SCRIBE, CRISPR BY DESIGN, and X SCRIBE THERAPEUTICS. These are among 3 currently registered trademarks in the portfolio.
What is Scribe Therapeutics Inc.'s trademark registration success rate?
Scribe Therapeutics Inc. has a 43% trademark registration rate, with 3 out of 7 resolved applications resulting in successful registration. Currently, 3 applications are pending review.